Pfizer Inc (PFE)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 1,043,000 | 1,092,000 | 1,052,000 | 719,000 | 2,853,000 | 3,148,000 | 2,632,000 | 2,166,000 | 416,000 | 1,298,000 | 1,780,000 | 2,470,000 | 1,944,000 | 1,966,000 | 2,372,000 | 1,768,000 | 1,784,000 | 1,587,000 | 1,801,000 | 2,151,000 |
| Short-term investments | US$ in thousands | 19,434,000 | 8,860,000 | 6,049,000 | 11,209,000 | 9,837,000 | 41,033,000 | 42,153,000 | 17,806,000 | 22,316,000 | 34,825,000 | 31,524,000 | 21,427,000 | 29,125,000 | 27,730,000 | 19,328,000 | 11,899,000 | 10,437,000 | 8,912,000 | 9,581,000 | 8,200,000 |
| Total current liabilities | US$ in thousands | 42,995,000 | 43,211,000 | 43,819,000 | 40,497,000 | 47,794,000 | 31,136,000 | 34,647,000 | 36,562,000 | 42,138,000 | 44,314,000 | 47,410,000 | 39,268,000 | 42,671,000 | 41,803,000 | 35,664,000 | 26,652,000 | 25,920,000 | 34,154,000 | 32,723,000 | 33,890,000 |
| Cash ratio | 0.48 | 0.23 | 0.16 | 0.29 | 0.27 | 1.42 | 1.29 | 0.55 | 0.54 | 0.82 | 0.70 | 0.61 | 0.73 | 0.71 | 0.61 | 0.51 | 0.47 | 0.31 | 0.35 | 0.31 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,043,000K
+ $19,434,000K)
÷ $42,995,000K
= 0.48
The cash ratio of Pfizer Inc has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The cash ratio measures the proportion of a company's current assets held in cash or cash equivalents relative to its current liabilities.
From March 31, 2020, to June 30, 2021, the cash ratio steadily increased from 0.31 to 0.61, indicating an improvement in Pfizer's liquidity position. The ratio peaked at 1.42 on September 30, 2023, signaling a significant increase in the company's ability to cover its short-term obligations with cash on hand.
However, the cash ratio declined in the subsequent periods, reaching 0.16 on June 30, 2024, before slightly recovering to 0.48 by December 31, 2024. The decreasing trend in the cash ratio towards the end of the period may suggest that Pfizer's liquidity position weakened, potentially due to changes in the company's cash holdings or current liabilities.
Overall, the cash ratio analysis indicates that Pfizer Inc experienced fluctuations in its liquidity levels over the analyzed period, with periods of improvement followed by declines. It is important for investors and analysts to monitor changes in the cash ratio to assess the company's ability to meet its short-term financial obligations.
Peer comparison
Dec 31, 2024